Uncategorized
GSK, Spero’s oral antibiotic wins first FDA nod for complicated UTI
After being rejected in June 2022, GSK paid Spero Therapeutics $66 million for an exclusive worldwide license to develop and commercialize the drug. It’s the second oral antibiotic GSK has brought to market since the beginning of last year.